þ CD25 þ FOXP3 þ T regulatory cells (T regs ) prevent autoimmunity by restricting overexuberant immune responses, but the same subpopulation can incur detrimental effects on antitumor responses. In both cases, the suppressor potential of T regs appears to be strongly influenced by their compartmentalization. In myelodysplastic syndromes (MDS), immune deregulation and autoimmunity in the early stages might lead to ineffective hematopoiesis and bone marrow (BM) failure, whereas late-stage disease is characterized by the immune escape of the malignant clone. We show that these two stages of MDS are associated with differential T reg activity. Specifically, we found that in early stage MDS, compared with normal hematopoiesis and late stage MDS, T regs are dysfunctional and their BM homing through the CXCL12/CXCR4 axis is seriously impaired as a result of CXCR4 downregulation. Conversely, in late stage MDS, T regs are systemically and locally expanded and retain their function and migratory capacity. Moreover, T reg levels follow the disease course and are significantly reduced in treatment responding patients. Our findings indicate T reg involvement in the pathophysiology of MDS; defective suppressor function and BM trafficking of T regs may be important in the autoimmune process of early MDS, but increased T reg activity could favor leukemic clone progression in late stage disease.
Introduction

CD4
þ CD25 þ FOXP3 þ T regulatory (T regs ) cells maintain immunological tolerance by actively suppressing immune responses. 1, 2 Increased T reg activity may protect from autoimmunity, [3] [4] [5] but impairs immune surveillance and antitumor immune responses. 6, 7 On the other hand, reduced T reg activity is associated with the development of autoimmunity 8, 9 and more effective immune surveillance. [10] [11] [12] Numerous data suggest that selective migration to and retention of T regs at sites of inflammation by altering their homing receptors is required for the effective suppression of local immune responses. 13 The induction of diabetes in nonobese diabetic mice was hampered only when the transferred T regs were able to migrate to lymph nodes through CD62L expression.
14 Also, abrogation of CCR4 expression on T regs resulted in severe cutaneous and pulmonary inflammation, 15 whereas fully competent T regs from FucTVII À/À mice that lack E-and P-selectin ligands could not prevent footpad swelling in a Th1-mediated delayed type hypersensitivity model. 16 Expression of another chemokine receptor, namely CXCR4, has been reported to be essential for the recruitment and accumulation of T regs into human bone marrow (BM) by CXCR4/CXCL12 signals, 17 indicating a potential immunoregulatory role of the latter.
Myelodysplastic syndromes (MDS) comprise a group of clonal hematopoietic stem cell disorders typically associated with immunologic abnormalities. Several lines of evidence, such as the presence of autoreactive T-cell clones and increased levels of preapoptotic cytokines, suggest that immune deregulation, especially in early MDS, results in an autoimmune process leading to ineffective hematopoiesis and BM insufficiency and in, up to 30%, systemic autoimmunity. 18, 19 Furthermore, immunosuppressive and immunomodulatory agents induce favorable clinical responses in subsets of patients with lowgrade disease, 20, 21 further arguing for an autoimmune component in the pathogenesis of MDS. In contrast to early stages, progression of MDS is characterized by the immune evasion and selective growth advantage of the leukemic clone.
The coexistence of malignancy with autoimmunity and immune-mediated BM failure in MDS tempted us to speculate that these processes might be subject to aberrant regulation by T regs . To address this, we first studied T reg number, frequency and function in both the peripheral blood (PB) and BM from a large cohort of patients with early and late MDS. Subsequently, we addressed the differences in the chemokine receptor profile and BM homing properties of T regs between normal individuals and MDS patients. We show here that T regs expand in both the PB and BM of MDS patients during disease progression, whereas tumor load reduction after chemotherapy is accompanied by a significant decrease in T regs . Also, T reg suppressor function and BM trafficking through the CXCL12/CXCR4 axis are significantly compromised in early MDS stages, in contrast to late stages where T regs display normal suppressive and migratory properties.
Patients, materials and methods
Patients
Peripheral blood, BM and BM fluid (that is, cell-free BM) samples were obtained from 63 (40 male, 23 female) treatmentnaïve MDS patients with a median age of 68 years (range: 39-85). Patients were further divided into two subgroups based on International Prognostic Scoring System (IPSS) score: early stage MDS (E-MDS, low/intermediate-1 risk, n ¼ 44) and late-stage MDS (L-MDS, intermediate-2/high risk, n ¼ 19). According to the World Health Organization's classification, two (3%) patients had 5q-syndrome, 9(14%) refractory anemia (RA), 24(38%) refractory anemia with multilineage dysplasia (RCMD), 14(22.5%) refractory anemia with excess blasts-I (RAEB-I), 8(13%) refractory anemia with excess blasts-II (RAEB-II) and 6(9.5%) refractory anemia with ringed sideroblasts with or without multilineage dysplasia (RAS/RAS-RCMD). Sixty-two percentage of the patients had normal cytogenetics, 23% had a single and 13% complex karyotypic abnormalities. Twentyeight hematologically normal age-matched individuals (16 male, 12 female; age range: 23-82 years), 14 of them undergoing orthopedic surgery, were used as controls. The study was approved by the local ethics committee and an informed consent was obtained from all patients and controls.
Immunophenotypic analysis
Whole PB and BM samples were stained with the following antibodies after erythrocyte lysis with ammonium chloride: CD4-PERCP, CD25-PE, CD25-APC, CXCR4-APC, CD45R0-PE, CD45RA-FITC, and the appropriate isotypic controls, all from Becton Dickinson Hellas S.A., Greece. Intracellular staining for FOXP3-FITC and FOXP3-PE (clone 259D/C7) was performed according to manufacturer's instructions (Becton Dickinson Hellas S.A., Greece). Data acquisition and analysis were performed on a FACSCalibur, equipped with CellQuest Pro software (Becton Dickinson Hellas S.A., Greece).
Cell isolation
Mononuclear PB and BM cells were isolated after density centrifugation. CD4 þ , CD4 þ CD25 high and CD4 þ CD25
À T-cells from PB and BM were purified by using a commercial kit (CD4 þ CD25 þ human regulatory cell isolation kit, Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions, slightly modified to achieve higher purities of CD4 þ CD25 high T-cells. 22 In addition, as the isolation kit is designed for PB, BM CD4 þ CD25 À T cells were further enriched by one more incubation step with CD4-PE/anti-PE MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) to efficiently remove all CD25 þ cells. Isolated subpopulations routinely showed 490% purity; CD4 þ CD25 high T-cells were also 490% FOXP3 þ (Figure 3a ).
Proliferation assays
The regulatory properties of CD4 þ CD25 high T regs were assessed in carboxyfluorescin-diacetat-succinimidyl-ester (CFSE)-based proliferation assays on a per cell basis. CFSE (Sigma-Aldrich (OM) Ltd., Greece) labeled responder CD4 þ CD25 À T-cells (T resp , 5Â 10 4 /well) were cultured in duplicate in 96-well U-bottom plates after stimulation with of soluble anti-CD3 and anti-CD28 (Dynabeads CD3/CD28 T Cell Expander, Dynal Biotech, Oslo, Norway), either alone or with sorted autologous CD4 þ CD25 high T regs at the indicated ratios. After 72 h, cell proliferation was assessed by CFSE dilution after dead cell exclusion by PI (propidium iodide) staining. Proliferation of T resp cells was expressed as the ratio of undivided cells in the absence of T regs (proliferation corresponding to 100%) to the undivided cells in the rest of the T reg :T resp ratios.
Cytokine detection
Culture supernatants from the proliferation assays described above were analyzed for interferon-g (IFN-g) and tumor necrosis factor-a (TNF-a) by using the human Th1/Th2 cytokine cytometric bead array Kit (Becton Dickinson Hellas S.A., Greece). CXCL12 and TNF-a were detected in BM fluid and serum by enzyme-linked Immunosorbent assay (R&D Systems, Abingdon, UK).
Chemotaxis assay
Purified PB CD4 þ cells from patients and controls were subjected in migration assays as described previously, 23 using CXCL12 and BM fluid as chemotactic media. All migration assays were performed in duplicates in 24-well plate tissue culture inserts with 5-mm pore polycarbonate filters (Costar Corporation, Cambridge, MA, USA). Briefly, magnetic antibody cell sorting (MACS)-purified PB CD4 þ T cells from patients and controls CD4
þ cells (10 6 /well) were induced to migrate toward either CXCL-12 (100 ng/ml; R&D Systems) or BM fluid from patients or normal donors, always diluted 1:4 in migration medium (0.5% bovine serum albumine (BSA), 10 mM Hepes, 10% FCS in RPMI medium 1640). After 3 h, migrated cells were quantified by flow cytometry, using fluorescent beads (Becton Dickinson Hellas S.A., Greece), and stained with CD4, CD25 and antihuman FOXP3 antibodies. Dead cells were excluded with PI staining. The absolute number of migrated T regs was calculated by multiplying the percentage of FOXP3 þ /PI À cells with the total number of CD4 þ /PI À migrated cells, and T reg migration was expressed as the percentage of the starting T reg population that migrated during the incubation period. CXCR4 neutralization experiments were performed by incubating cells with mouse antihuman CXCR4 (100 ng/ml; clone 12G5, R&D Systems) for 30 min before addition to the top chamber.
Statistical analysis
All analyses were performed using SPSS 14.0 software (SPSS Science, Chicago, IL, USA). Data are presented as mean ± s.e.m. The significance of the differences was assessed by one-way ANOVA (analysis of variance) or paired Student's t-test as appropriate.
Results
T reg kinetics in MDS in relation to the disease course and response to therapy
Using multicolor flow cytometry, we initially assessed the frequency and absolute number of CD4 (Figures 1a and b) and BM (Figure 1c ) of patients and healthy donors. In agreement with a previous report, 24 we found significant T reg expansion in PB during the late MDS stages and disease progression. The absolute count of T regs showed a more than twofold increase in L-MDS patients (17.5 ± 1.7 cells/ml), compared with both normal individuals (7.67 ± 0.6 cells/ml; Po0.001) and E-MDS patients (6.99 ± 0.57 cells m/l; Po0.001). Similarly, L-MDS patients displayed significantly higher PB T reg frequency (2.5±0.19%), compared with controls (1 ± 0.07%, Po0.001) and E-MDS patients (1.35 ± 0.19%, Po0.001). Identical results were observed regarding T reg levels in the BM of L-MDS (2.31 ± 0.38%) and E-MDS (0.84 ± 0.12%; Po0.001) patients and normal donors (1.16±0.07%; P ¼ 0.004). No statistically significant differences in the frequency and absolute numbers of either PB or BM T regs occurred among L-MDS patients and normal controls. Notably, both in PB and BM, the naïve CD45RA þ T regs were predominantly expanded ( Figure 1d ).
Next, we investigated changes in T reg number and frequency during the course of MDS. T reg levels in PB were profoundly increased in three L-MDS patients who progressed to overt leukemia (Figure 2b ), whereas they remained unchanged in either E-MDS (n ¼ 14) or L-MDS (n ¼ 6) patients with stable disease over a period of more than 9 months (range: 9-14 months, Figure 2a ). In addition, a more than threefold reduction in both PB and BM T reg count and frequency was observed in two L-MDS patients after induction chemotherapy and partial disease remission (Figure 2b ). Notably, T regs reincreased to pretreatment levels in the above patients that relapsed soon after chemotherapy ( Figure 2c ).
Taken together, these results suggest that CD4 þ CD25 þ FOXP3 þ T reg kinetics follow the disease course, severity and treatment response.
Peripheral blood and BM T regs are dysfunctional in early stage MDS
In several autoimmune diseases, T regs exert defective suppression despite normal numbers and frequency. 3, 9, 25 Because systemic and local immune dysfunction actively participates in the pathophysiology of MDS, 18, 19, 21 we investigated whether a similar phenomenon occurs in the latter.
To assess the function of T regs at the single cell level, we employed proliferation assays of PB and BM-derived MACSpurified CD4 þ CD25 high and CD4 þ CD25 À T cells (T resp , Figure 3a ). We found that in E-MDS patients, T regs from PB as well as from BM were less efficient in suppressing autologous polyclonal T-cell proliferative responses compared with normal individuals (Po0.001 in both PB and BM, Figures 3b and c) and L-MDS patients (Po0.001 in both PB and BM, Figures 3b and c) . The defect in the suppressor activity of T regs in E-MDS was evident in all T reg :T resp ratios ( Figure 3d ).
Given that BM failure in low-risk MDS is largely mediated by proinflammatory cytokines, 18, 19, 21 we also assessed the Treginduced inhibition of IFN-g and TNF-a production in the supernatants of proliferation assays (Figures 4a-c) . Measurement of these two important mediators of the immune attack against BM hematopoiesis in MDS, yielded comparable results with the in vitro inhibition of T resp proliferation. PB T regs from E-MDS patients failed to suppress IFN-g production from stimulated autologous CD4 þ CD25 À compared with normal controls (P ¼ 0.002) and L-MDS patients (P ¼ 0.025). Similarly, the inhibition of TNF-a secretion from PB T regs was noticeably weaker in E-MDS patients in comparison to normal individuals (P ¼ 0.001) and L-MDS patients (P ¼ 0.13). The defective inhibition of cytokine release was also evident in the proliferation assays with BM T regs from E-MDS patients. Suppression of cytokine production was markedly impaired in E-MDS patients compared with normal donors (P ¼ 0.088 and P ¼ 0.029, for IFN-g and TNF-a, respectively) and L-MDS patients (P ¼ 0.036 and P ¼ 0.4, for IFN-g and TNF-a, respectively). As it applied to T reg frequency and numbers, no differences in T reg suppressor function and inhibition of cytokine secretion were observed between L-MDS patients and controls.
Thus, T reg suppressive function at the single cell level is severely compromised during the early stages of MDS, whereas it is retained in L-MDS patients, which also display a significant numerical increase of T regs .
T regs in early stage MDS display lower CXCR4 expression and impaired BM homing Appropriate compartmentalization of T regs is considered to be critical for the effective regulation of immune responses. 15, 16, 26 In low-risk MDS, BM is the target organ of an immune-mediated suppression of hematopoiesis that results in hematopoietic insufficiency. Thus far, the only chemokine known to attract T regs in human BM is CXCL12, which interacts with CXCR4 expressed on T regs . 17 To investigate whether the dysfunction of T regs in E-MDS includes also defective migration toward BM through the CXCL12/CXCR4 axis, we first studied the expression of CXCR4 in PB T regs from normal controls and MDS patients. We found that a significantly lower proportion of T regs from E-MDS patients expressed CXCR4 (15.8±1%) compared with normal controls (24.9 ± 1.3%, P ¼ 0.002) and L-MDS patients (25.9 ± 3.3%, Po0.001, Figures 5a and b) , suggesting decreased BM homing potential. In line with this finding, PB T regs from E-MDS patients exhibited decreased in vitro chemotaxis in response to CXCL12 compared with controls (P ¼ 0.036) and L-MDS patients (P ¼ 0.086, Figure 5c ). By contrast, T regs from normal controls and L-MDS patients displayed comparable CXCR4 expression and chemotaxis. Moreover, blocking of CXCR4 with the 12G5 mAb resulted in significant reduction of T reg migration (P ¼ 0.036), confirming that the observed chemotaxis was specific and mediated through CXCL12/CXCR4 signals (Figure 5c ).
To exclude the possibility that alterations in the secretion of CXCL12 or other soluble T reg chemoattractant from BM is responsible for the impaired T reg chemotaxis in E-MDS, migration assays were performed using BM fluid from patients and controls as the chemotactic substance. Migration of normal PB CD4 þ CD25 þ FOXP3 þ cells was similar in all groups (Figure 6a ). Likewise, levels of CXCL12 in BM supernatants were comparable among all groups (E-MDS: 4.98±1.57 ng/ml, L-MDS: 5.33 ± 1.9 ng/ml, controls: 4.1 ± 1.2 ng/ml, Figure 6b ), indicating that the attenuation of chemotactic signals from BM is not responsible for the defective migration of T regs in E-MDS. Finally, consistent with a reduced in vivo migratory potential exclusive to E-MDS, the BM frequency of T regs from these patients was significantly reduced as compared with PB (0.78±0.14 vs 1.33±0.22%, respectively; Po0.001, Figure 5c ), whereas T reg levels were identical in both cellular compartments of normal individuals (PB: 1.13±0.12%, BM: 1.16 ± 0.1%) and L-MDS patients (PB: 2.34 ± 0.35%, BM: 2.33±0.45%).
Discussion
There is a long-known association of MDS with autoimmune manifestations and immune-mediated BM failure.
þ naturally occurring T regs are essential for the control of the self-tolerance, but are believed to exert antithetical effects in the regulation of tumor immunity and immune homeostasis. 6, 28 Recently, it has been shown that three lymphocyte subpopulations with regulatory potential, namely invariant natural killer T, 29 NK 30,31 and gd-T 32 cells are reduced and dysfunctional in MDS patients, thus enforcing the notion of defective immune surveillance in MDS. To our knowledge, there is currently only one study addressing T regs in MDS. Kordasti et al. 24 observed a polyclonal expansion of T regs in the PB of patients with high-risk MDS. However, the kinetics and the functional and migratory properties of T regs were not assessed, and the study was restricted to PB T regs only. 24 In the present study, we show that, depending on disease stage and aggressiveness, both PB and BM T regs in MDS patients display numerical and functional alterations.
A significant expansion of T regs was noted in both the PB and BM of our L-MDS patients, in contrast to E-MDS patients, which displayed normal T reg levels. Additionally, the finding that in patients with stable disease, independently of stage, there were no fluctuations in T reg numbers, whereas leukemic progression was characterized by a remarkable expansion of PB and BM T regs further suggests T reg involvement in the pathophysiology of MDS. These results are in line with numerous reports showing a marked increase of T regs in various solid and hematological malignancies.
22,33-38 Even though still poorly understood, it T reg kinetics, function and trafficking in MDS I Kotsianidis et al seems that this expansion may be tumor-associated antigen (TAA) driven, as T reg clones can be generated by tumorassociated antigens and tumor-specific T regs can efficiently suppress TAA-specific immune responses. 39, 40 The dramatic decline in T regs after tumor load reduction in high-risk MDS patients as well as their re-elevation, when these patients relapsed, further argues for tumor antigen-specific expansion of T regs in advanced stages of MDS.
Although quantitative T reg abnormalities are most frequently described, isolated defects of the suppressive capacity of T regs in autoimmune diseases have also been reported, 3, 9, 25 making the assessment of their function essential. T reg dysfunction in autoimmunity is likely to occur because of TNF-a overproduction, which has been shown to be a negative regulator of T reg function in mice, 4 normal individuals 41 and patients with rheumatoid arthritis, who restored their T reg activity after administration of anti-TNF-a treatment. 3 Normal levels of T regs , but with significantly compromised suppressor potential and inhibition of proinflammatory cytokine production by CD4 þ CD25 À effector cells were observed in both the PB and BM of our E-MDS patients. On the contrary, in L-MDS, T regs were expanded and their function was intact. The biologic basis of these findings is unclear. A possible explanation may be that the observed expansion of T regs in L-MDS patients consists mainly of new TAA-specific clones with normal suppressive function that emerge as a result of the uncontrolled growth of the preleukemic clone, and therefore abundance of tumor antigen. Pertinent to this, we found a significant increase of þ CD25 À responders (T resp , 5 Â 10 4 /well) from patients with E-MDS (ii), L-MDS (iii) and normal donors (iv) were stained with CFSE and cultured in the presence of soluble CD3 and CD28 either alone (i) or with CD4 þ CD25
hi T regs at a 1:2 T reg :T resp ratio (ii, iii and iv). On day 3, cells were collected and stained with anti-CD25 and propidium iodide. Plots are gated on live cells. Right upper quadrant percentages represent the undivided cells. (c) Cumulative results of proliferation assays in PB (black bars) and BM (gray bars) carried out at a 1:2 and 1:5 T reg :T resp ratio, respectively. Both PB and BM-derived T regs from E-MDS patients were significantly less suppressive compared to those in L-MDS patients and normal controls. Results are presented as mean ± s.e.m. of duplicate cultures, and expressed as the percentage of proliferation relative to a 0:1 T reg :T resp , designated as 100%. (d) The defective suppressive capacity of T regs in E-MDS was observed in all T reg :T resp ratios. Mean values of five separate experiments in each group are shown. Ctrl, control; **Po0.001 by one-way ANOVA. BM, bone marrow; CFSE, carboxyfluorescindiacetat-succinimidyl-ester; E-MDS, early-stage MDS; PB, peripheral blood; L-MDS, late-stage MDS; T regs, T regulatory cells.
T reg kinetics, function and trafficking in MDS
I Kotsianidis et al naïve CD45RA þ T regs in both the blood and BM of L-MDS patients. Such an expansion occurs also in multiple myeloma potentially because of peripheral expansion as deduced by the low frequencies of T-cell receptor excision circles found in naïve T regs . 22 Interestingly, naïve T regs have been shown to possess different functional properties than memory ones, such as resistance toward CD95L-mediated apoptosis. 42 Another possibility for the differential T reg activity in early and late MDS is the variations in TNF-a levels according to the stage of the disease. It has been shown that TNF-a is overexpressed in the early stages of MDS, but is downregulated during disease progression. 43 Analogous oscillations of TNF-a expression was found in our patient cohort, both in the serum and BM fluid (data not shown). T reg trafficking and compartmentalization appears to shape their suppressor potential. 13 Experimental data from murine models suggest that the entry of T regs in inflammatory tissues is indispensable for the resolution of a local reaction, 14, 16, 44, 45 whereas inflammation in various tissues can be triggered merely by changes in T reg tissue distribution. 15 In early MDS stages, BM is targeted by an autoimmune assault, which induces high levels of local inflammation and eventually marrow failure. We show for the first time that, in addition to defective suppressor function, T regs from E-MDS patients also exhibit impaired BM homing. The in vitro chemotaxis of T regs through the CXCL12/ CXCR4 axis, which is utilized by T regs for BM homing, 17 was significantly decreased in E-MDS patients compared with normal donors and L-MDS patients. The potential cause of this phenomenon was the reduced expression of CXCR4 on T regs in E-MDS, as BM fluids from patients and donors did not induce any differences in the migration of normal T regs from the same donor, and CXCL-12 BM levels were similar in all groups. Why CXCR4 is downregulated on T regs in E-MDS is difficult to explain. Memory T-cell subsets in systemic lupus erythematosus have also decreased CXCR4 levels compared with their normal counterparts, potentially reflecting an activated status because of chronic in vivo stimulation. 46 An analogous mechanism could also apply to our case, as low-risk MDS is frequently associated with an autoimmune background. Moreover, the expansion T regs in L-MDS has been reported to be of predominantly naïve subtype, 24 which may account for the restoration of CXCR4 expression in the T regs of these patients, as naïve T cells have generally higher CXCR4 levels than the memory ones. 47 Whichever the mechanism, the significant decrease of T regs in the BM as compared with PB, observed exclusively in E-MDS patients, is illustrative of an in vivo reduced T reg BM trafficking, thus providing further support to our in vitro data.
In conclusion, T regs from E-MDS patients have a reduced ability to suppress immune responses and, through reduced expression of CXCR4, impaired BM trafficking. This is associated with a reduction of T regs in the BM microenvironment and might be a significant mechanism underpinning the immune deregulation, autoimmunity and eventually BM failure observed in E-MDS. On the contrary, in L-MDS, increased numbers of PB and BM T regs that retain their suppressive function and migratory capacity may result in impaired local immune surveillance and favor the escape of the preleukemic clone. The above data along with T reg kinetics in stable and progressive disease and after reduction of tumor burden by chemotherapy would suggest that alterations in the dynamics and function of T regs could be a parameter determining disease progression; study of more patients will be needed to establish whether this indeed is the case. Analogous to our findings in E-MDS patients, T reg deficiency has also been reported in idiopathic aplastic anemia, 48 further supporting a shared and overlapping pathogenesis between the two disorders. In addition, as in L-MDS, an expansion of functionally normal T regs is observed in patients with acute leukemia, 35 providing further evidence for a link between T reg -mediated immunomodulation and malignant hematopoiesis.
Given the effectiveness of immunosuppressive regimens in MDS and the encouraging results of the T reg immunotherapy in solid neoplasms and autoimmune conditions, 49, 50 our findings set the scene for the incorporation of the therapeutic manipulation of T regs in MDS. 
